01-26-04

PTO/SB/21 (03-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of iformation unless it contains a valid OMB control ber.

number.			Application Number	10	/696,261
			Filing Date		ctober 29, 2003
TRA	NSMITTAL		First Named Inventor		
	FORM 🐎				mes M. Wilson et al
	•		Group Art Unit	16	35
(to be used for all co	rrespondence after initial fi	ing)	Examiner Name	Bı	rian A. Whiteman
Total Number of Pages in	n this Submission		Attorney Docket Number	G	NV31CUSA/K1774DIV2
rotal Number of Pages in	<u>-</u>	11 NCLOS	SURES (check all tha	t app	lv)
Fee Transmittal	Form		Orawing(s)		After Allowance Communication
Fee Attached		ا 🗆 ر	icensing-related Papers		to Group Appeal Communication to Board
Amendment/Rep	ily	□₽	Petition		of Appeals and Interferences
After Final	•		Petition to Convert to a Provisional Application		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
Affidavits/dec	laration(s)		Power of Attorney, Revocation		Proprietary Information
Extension of Tim	e Request		hange of Correspondence		Status Letter
Express Abando	nment Request	╻╻	erminal Disclaimer		Other Enclosure(s) (please
Information Disci	osure Statement		Request for Refund		identify below):
Certified Copy of Document(s)	Priority	CD, Number of CD(s)			4- Copies of references
Response to Mis		Rema	arks		
Response to N					
under 37 CFR	1.52 or 1.53				
	SIGNAT	URE O	F APPLICANT, ATTORNE	Y, OR	AGENT
Firm or	Howson and Ho	owson			
Individual Name	Cathy A. Kodro	off ,			
Signature Charles Ko			leaf		
Date	January 23, 200	4	W		
	CE	RTIFIC	ATE OF TRANSMISSION/	MAIL	ING
					ne United States Postal Service with sufficient ndria, VA 22313-1450 on this date:
Typed or printed name	Э				
Signature				Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1 -800-PTO-9199 (1-800-786-9199) and select option 2. . .

Customer No. 00270



GNV31CUSA/UPN-K1774DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of James M. Wilson) Group Art Unit: 1635
James IVI. Wilson) Examiner: Brian A. Whiteman
Appln. No. 10/696,261) Confirmation No. 7899
Filed: October 29, 2003)
For: ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST)))
CELLS CONTAINING SAME) January 23, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B and this paper identify documents previously cited in grandparent application, US Patent Application No. 09/807,802, filed November 29, 2001, which is a national phase of PCT/US99/25694 filed November 2, 1999, which claims the benefit of the priority of US Patent Application No. 60/107,114, filed November 5, 1998 and parent US Application No. 10/696,282, which is pending.

According to 37 CFR § 1.98(d), Applicants have not enclosed copies of any US Patents, Publications or other documents listed herein, which listed items were previously cited by or submitted to the United States Patent and Trademark Office in prior grandparent US Patent Application No. 09/807,802, filed November 29, 2001 and parent US Patent Application No. 10/696,282, filed October 29, 2003.

Express Mail No. EU531570417US

REMARKS

Listed below are previously filed, co-pending, co-owned U.S. Patent Applications. This application and the present application are commonly owned: Copies of the application and claims area enclosed.

. . . .

- (1) U.S. Patent Application No. 09/807,802, November 29, 2001
- (2) U.S. Patent Application No. 09/665,852, September 20, 2000
- (3) U.S. Patent Application No. 10/696,282, October 29, 2003
- (4) U.S. Patent Application No. 10/696,900, October 30, 2003

This application is relied upon for an earlier effective filing date under 35 USC § 120. The IDS submitted in the earlier application complies with paragraphs (a) through (c) of 37 CFR § 1.98(d).

This Information Disclosure Statement is submitted within three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for Applicant

Cathy A/Rodroff

Registration No. 33,980

Spring House Corporate Center

Box 457

Spring House, PA 19477 Phone: (215) 540-9200

Fax: (215) 540-5818



PTO/SB/08B (04-03)

Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Co	mplete if Known	
Application Number	10/696,261	
Filing Date	October 29, 2003	
First Named Inventor	James M. Wilson	
Group Art Unit	1635	
Examiner Name	Brian A. Whiteman	
Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2	

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number Publication Date		Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages		
Initials*	No.1	Number-Kind Code 2(11 Known)	MM-DD-YYYY	Cited Document	or Relevant Figures Appear		
	Α	US-6,387,368 B1	05-14-2002	Wilson et al			
	В	US-6,274,354 B1	08-14-2001	Wilson et al			
	C	US-6,482,634 B1	11-19-2002	Wilson et al			
	D	US-6,475,769 B1	11-05-2002	Wilson et al			
	E	US-6,365,394 B1	04-02-2002	Gao et al			
	F	US-6,399,385 B1	06-04-2002	Croyle et al			

		FOREIGN E	PAT	TENT DOCUMENTS			
		Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines, Where	Т°
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ -Kind Code ⁵ (If known)		Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	G	PCT WO03/093440 A	2	11-13-2003	University		
					of Florida		
	Н	PCT WO03/092598 A	2	11-13-2003	University		
					of Florida		
	I	PCT WO98/11244 A	2	03-19-1998	J. Chiorini		

Examiner	Date	
Signature	Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

contains a valid OMB control number.

2

Sheet

Substitute for form 1449/PTO	:
INFORMATION	
DISCLOSURE	
STATEMENT BY	
APPLICANT	
(Use as many sheets as necessary)	

of

8

Complete if Known					
Application Number	10/696,261				
Filing Date	October 29, 2003				
First Named Inventor	James M. Wilson				
Group Art Unit	1635				
Examiner Name	Brian A. Whiteman				
Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2				

U.S. PATENT DOCUMENTS					
Examiner	Cite Document Number		Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages
Initials*	No.1	Number-Kind Code ^{2(ffknown)}	MM-DD-YYYY	Cited Document	or Relevant Figures Appear
	J	US-5,871,982 B1	02-16-1999	J. Wilson	
	K	US-6,258,595 B1	07-10-2001	G. Gao	
	L	US-6,274,354 B1	08-14-2001	J. Wilson	
· · · · · · · · · · · · · · · · · · ·	M	US-6,251,677 B1	06-26-2001	J. Wilson	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ -Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т ⁶		
	N	PCT WO96/13598 A2	05-09-1996	J. Wilson				
	0	PCT WO98/10088 A1	03-12-1998	J. Wilson				
	P	PCT WO98/10086 A1	03-12-1998	J. Wilson				
	Q	PCT WO99/15677 A1	04-01-1999	J. Wilson				
	R	PCT WO99/14354 A1	03-25-1999	J. Wilson				
	S	PCT WO99/15685 A1	04-01-1999	J. Wilson				
	T	PCT WO99/47691 A1	09-23-1999	G. Gao				
	U	PCT WO00/55342 A1	09/21/2000	G. Gao				
	V	PCT WO00/75353 A1	12-14-2000	W. Xiao				
Examiner Signature			Date Consid					

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain of retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents**, Alexandria, VA 22313-1450



PTO/SB/08B (04-03) Approved for use through 4/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction ACT of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
INFORMATION
DISCLOSURE
STATEMENT BY
APPLICANT

3

Sheet

APPLICANT
(Use as many sheets as necessary)

of

8

Complete if Known						
Application Number	10/696,261					
Filing Date	October 29, 2003					
First Named Inventor	James M. Wilson					
Group Art Unit	1635					
Examiner Name	Brian A. Whiteman					
Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2					

	U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Document Number Publication Date		Pages, Columns, Lines, Where Relevant Passages	
Initiais*	No.1	Number-Kind Code ^{2(ifknown)}	MM-DD-YYYY	or Applicant of Cited Document	or Relevant Figures Appear	
	W	US-6,156,303	12-05-2000	Russell et al		
	X	US-5,622,856	04-22-1997	Natsoulis		

	FOREIGN PATENT DOCUMENTS									
		Foreign Patent Document			Pages, Columns,	T ⁶				
Examiner Initials*	Cite No. ¹		Name of Patentee or Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures Appear						
	Y	PCT WO01/23597 A2	04-05-2001	G. Gao						
	Z	PCT WO01/23001 A2	04-05-2001	M. Croyle						
	AA	PCT WO01/83692 A2	11-08-2001	M. Hildinger						
"."	BB	PCT WO01/40455 A2	06-07-2001	G. Gao						

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CEP 1.97 and 1.98. The information is required to obtain or retain a

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-00)

Approved for use through 4/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

Substitut	ubstitute for form 1449/PTO			Complete if Known		
	INFO	RMA	TTON	Application Number	10/696,261	
		CLOS		Filing Date	October 29, 2003	
	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	James M. Wilson	
				Group Art Unit	1635	
<i>(</i>				Examiner Name	Brian A. Whiteman	
Sheet	4	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2	

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T²
	CC	HAUCK ET AL, Generation and Characterization of Chimeric	
		Recombinant AAV Vectors, Molecular Therapy, Vol. 7, No. 3,	
		pp. 419-425, (March 2003)	
	DD	RABINOWITZ ET AL, Cross-Packaging of a Single Adeno-	
		Associated Virus (AAV) Type 2 Vector Genome into Multiple	
		AAV Serotypes Enables Transduction with Broad Specificity,	
		Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2002)	
	EE	HAUCK ET AL, Characterization of Tissue Tropism Determinants	
		of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 77,	
		No. 4, pp. 2768-2774, (February 2003)	
	FF	ARRUDA ET AL, Safety and Efficacy of Factor IX Gene Transfer	
		to Skeletal Muscle in Murine and Canine Hemophilia B Models by	İ
	İ	Adeno-Associated Viral Vector Serotype 1, Blood First Edition	
		Paper, (September 11, 2003)	
	GG	E. RUTLEDGE ET AL, Infectious Clones and Vectors Derived	
		from Adeno-Associated Virus (AAV) Serotypes Other Than AAV	
	}	Type 2, Journal of Virology, 72(1):309-319 (January, 1998)	

Examiner	Date
Signature	Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.



Approved for use through 4/30/2003.

OMB 0651-0031

U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it valid OMB control number.

Substitute	Substitute for form 1449/PTO			Complete if Known		
	TNEO	RMΔ'	TTON	Application Number	10/696,282	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	October 29, 2003	
				First Named Inventor	James M. Wilson	
				Group Art Unit	1635	
(1				Examiner Name	Brian A. Whiteman	
Sheet	5	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2	

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T ²
	НН	W. XIAO ET AL, Gene Therapy Vecotrs Based on Adeno- Associated Virus Type 1, Journal of Virology, 73(5):3994-4003	
		(May, 1999)	ļ
	II	H. CHAO ET AL, Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors, Molecular Therapy, 2(6):619-623 (December 2000)	
	JJ	R. KOTIN ET AL, Site-Specific Integration by Adeno-Associated Virus, Proc. Natl. Acad. Sci. USA, 87:2211-2215 (March, 1990)	
	KK	K. FISHER ET AL, Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy, Nature Medicine, 3(3):306-312 (March, 1997)	
	LL	X. XIAO ET AL, Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-Associataed Virus Vector, Journal of Virology, 70(11):8098-8108 (November, 1996)	

Examiner	Date
Signature	Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office;

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it is a valid OMB control number.

Substitut	ubstitute for form 1449/PTO			Complete if Known		
	TNEC	DRMA	TION	Application Number	10/696,261	
INFORMATION DISCLOSURE				Filing Date	October 29, 2003	
STATEMENT BY				First Named Inventor	James M. Wilson	
	APPLICANT			Group Art Unit	1635	
(Use as many sheets as necessary)			ts as necessary)	Examiner Name	Brian A. Whiteman	
Sheet	6	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2	

	MM NN	R. SNYDER ET AL, Persistent and Therapeutic Concentrations of Human Factor IX in Mice After Hepatic Gene Transfer of Reocmbinant AAV Vectors, Nature Genetics, 16:270-276 (July, 1997)		
	NN		1	
	***	N. MUZYCZKA, Use of Adeno-Assicated Virus as a General Transduction Vector for Mamalian Cells, Current Topics in Microbiology and Immunology, 158:97-129, (1992)		
	00	R. SAMULSKI ET AL, Targeted Integration of Adeno-Associated Virus (AAV) into Human Chromosome 19, EMBO Journal, 10(12):3941-3950 (December, 1991)		
	PP	K. BERNS, Parvoviridae: The Viruses and Their Republication, in B. N. Fields et al, Fields Virology, 3 rd ed., Vol. 2, Chapter 69, pp. 2173-2197 (Lippincott-Raven Publishers, Philadelphia, PA) (1996)		
	QQ	R. SNYDER ET AL, Features of the Adeno-Associated Virus Origin Involved in Substrate Recognition by the Viral Rep Protein, Journal of Virology, 67(10):6096-6104 (October, 1993)		
RR K. BERNS, Parvovirus Replication, Microbiological Reviews, 54(3):316-329 (September, 1990)				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria VA 22313-1450



Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office;

U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

Substitut	ostitute for form 1449/PTO			Complete if Known		
	TNE	ЭРМА	TION	Application Number	10/696,261	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	October 29, 2003	
				First Named Inventor	James M. Wilson	
				Group Art Unit	1635	
(Use as many sheets as necessary)		Examiner Name	Brian A. Whiteman			
Sheet	7	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2	

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T ²
	SS	R. SAMULSKI ET AL, Cloning of Adeno-Associated Virus into pBR322: Rescue of Intact Virus from the Recombinant Plasmid in Human Cells, Proc. Natl. Acad. Sci. USA, 79:2077-2081 (March, 1982)	
	TT	J. CHIORINI ET AL, Cloning of Adeno-Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 Particles, Journal of Virology, 71(9):6823-6833 (September, 1997)	
	ŪŪ	S. MURAMATSU ET AL, Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3, Virology, 221:208-217, (1996)	
	VV	C. BALAGUE ET AL, Adeno-Associated Virus Rep78 Protein and Terminal Repeats Enhance Integration of DNA Sequences into the Cellular Genome, Journal of Virolgoy, 71(4):3299-3306 (April, 1997)	
	WW R. SUROSKY ET AL, Adeno-Associated Virus Rep Proteins Target DNA Sequences to a Unique Locus in the Human Genome, Journal of Virology, 71(10):7951-7959 (October, 1997)		
	XX	X. XIAO ET AL, Gene Transfer by Adeno-Associated Virus Vectors into the Central Nervous System, Experimental Neurology, 144:113-124 (1997)	

Examiner	Date
Signature	Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.



Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office;

U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

Substitute for form 1449/PTO)	Complete if Known	
	TNEC)PMA	TION	Application Number	10/696,261
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			-	Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
			ts as necessary)	Examiner Name	Brian A. Whiteman
Sheet	8	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T ²
	YY	ROSE ET AL, Microbiology, Vol. 546, Pages, 86-92, (1966)	
	ZZ	ANDERSON ET AL, Nature, Vol. 392, Pages, 25-30, (1998)	
	AAA	VERMA, Nature, Vol. 389, Pages 239-242, (1997)	
	BBB	ORKIN ET AL, Report and Recommendations of the Panel to Assess the NIH Investments in Research on Gene Therapy, issue by the National Institute of Health, (December 7, 1995)	

Examiner	Date	1
Landici		1
Signature	Considered	_

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation in not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.